ResApp (ASX: RAP) – Webinar Presentation
Tony Keating - CEO & Managing Director - ResApp is developing digital healthcare solutions to assist doctors and empower patients to diagnose and manage respiratory disease.
Read More
Resapp Health Limited
ResApp Health is developing healthcare solutions to assist doctors and empower patients to diagnose and manage respiratory disease on smartphones without the need for additional hardware.
ResApp’s core technology uses sound to diagnose respiratory diseases including pneumonia, bronchiolitis, bronchitis, chronic obstructive pulmonary disease, and asthma.
Spotlight Videos
ResApp (ASX: RAP) – Webinar Presentation
All Resapp Health Limited Content
News
ResApp (ASX: RAP) – Webinar Presentation
Dr Tony Keating - CEO & MD - ResApp is developing the world’s first COVID-19 instant screening test that will use cough sounds to indicate the presence of a COVID-19 infection.
Read More
Diagnosing COVID Via a Smartphone App
ResApp Health (ASX: RAP) is developing digital healthcare solutions to assist doctors and empower patients to diagnose and manage respiratory disease.
Read More
Digital health solutions for respiratory disease
Brian leedman - Executive Director & Corporate Affairs - ResApp is developing digital healthcare solutions to assist doctors and empower patients to diagnose and manage respiratory disease.
Read More
Resapp Health – ShareCafe Hidden Gems Webinar Presentation
Presenter – Tony Keating (CEO) – ResApp Health is developing healthcare solutions to assist doctors and empower patients to diagnose and manage respiratory disease on smartphones without the need for additional hardware.
Read More
Analyst Views
RAP – Morgans rates the stock as Add
The company has received Therapeutic Goods Administration approval for its paediatric cough diagnostic. This follows CE Mark approval for both children and adults which allows the company to market the device across Europe.
Read More
